bristol-my squibb compani bm engag discoveri develop licens manufactur market distribut
sale pharmaceut nutrit product compani two segment pharmaceut nutrit
pharmaceut segment made global pharmaceut intern consum medicin busi nutrit
segment consist mead johnson nutrit mead johnson primarili infant formula children nutrit busi
januari compani complet divestitur bristol-my squibb medic imag medic imag avista capit
partner june bm acquir kosan bioscienc inc develop oncolog product august compani
complet divestitur convatec busi cidron healthcar limit affili nordic capit fund vii
decemb bm complet sale brand busi egypt glaxosmithklin
rank
return equiti
price book
incom statement summari figur billion
global peer group analysi figur usd
compani
compani
hi
long-term fundament rank
short-term technic rank
rank number list
pharmaceut compani trade today unit state
market capit billion
pharmaceut compani highest total
asset highest revenu
within sector rel moder price-to-earnings high p/
strong rel roe roa
compani paid dividend last twelv month
dividend yield high
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
short term fall combin weak volum result
weak momentum fall day
significantli price premium
move averag price rang
trade discount
high premium low
invest exactli one year ago worth
capit gain dividend reinvest
stock score set
price perform trade
volum rank
accord averag
valu paramet
highest rank
lowest rank
bristol-my squibb compani place bss rank nyse perform past year percentil rank
bristol-my squibb compani new entrant boston consult group list top innov compani rank
rank mcap march pwc top global compani improv year rank
march
largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
product wast product carbon product
largest revenu forb global
new entrant industri week list world largest manufactur revenu rank
sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit billion aggreg sector net profit
billion previou year
ebit billion aggreg sector ebit
billion previou year
mcap billion aggreg sector mcap
billion previou year
discount high
premium low suggest stock
continu push new high
price/mov averag price macd
price/map higher price/map
indic exponenti move averag ema
minu ema posit suggest
price/map higher
price/map
price emap ratio bullish indic
past day ratio exceed time
suggest upsid emap increas
increas anoth bullish indic
price map ratio bullish indic
past day ratio exceed time
suggest upsid stock trade
map map higher
map bullish indic
map increas increas anoth
rise fall last three month number rise
outnumb fall
stock rel strength nyse
market mean beat market
price-to-earnings versu sector averag
market averag estim share trade
current year price-to-earnings forward year price-to-earnings
earn yield time bond yield
rel yield stock defin yield
divid averag yield dividend yield stock
suggest stock
under-valued dividend yield term
return equiti versu sector averag
market averag
total liabilities/ebitda less compar
favour joseph piotroski benchmark
return asset versu sector averag
market averag
return capit employ versu sector averag
market averag
net profit margin averag last year
consid superior suggest high margin safeti
per du pont analysi return equiti high
comput net profit margin time
asset turnov sales/asset time leverag factor
total assets/sharehold equiti
improv last year
market capit increas billion
billion billion last year
increas compris cumul retain earn rete
billion creat market valu billion
creat market valu multipl defin chang
mcap everi retain earn exemplari
trail twelv month price-to-earnings cyclic
adjust price earn cape cape
develop economist robert shiller base methodolog
benjamin graham david dodd smooth earn
across period base move averag
dividend yield time triple-a bond yield
benchmark set benjamin
growth quarterli revenu net incom
tobin ratio defin mcap divid total asset
compar rest market stock
overvalu rank bottom quartil stock valu
 ratio
averag annual compound return share price
last year under-perform averag
annual compound return
earn yield less benchmark yield
previou correspond period pcp quarterli revenu
million million
fall million million
ebit margin posit increas
past year
stock trade low today
past week volum time averag
share thursday close price
discount volum weight averag price vwap
present valu invest one month
ago bristol myer squibb capit loss
price/sal versu sector averag market
averag estim share trade
current year price/sal forward year price/sal
volum index average
stock trade low high
averag daili volatil place stock
quartil market mean mildli volatil
result report
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
amort acquir intang asset
provis incom tax
net earnings/ loss attribut bm
quarterli report sequenti growth
quarterli report analysi report sequenti rise quarterli revenu
sequenti growth ep
sequenti growth revenu
sequenti growth net profit
compar previou correspond period pcp year-over-year revenu
pcp growth revenu
major chang compar previou correspond period year-on-year
total revenu
ebitda sale
amortis sale
tax expens sale
result report annual
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
provis incom tax
net earn attribut bm
cash equival
prepaid expens
properti plant equip
pension liabil
author million share issu outstand
liquid valu per share
common stock par valu per share author billion
share billion issu
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock million common share
million common share
total liabil equiti
adjust reconcil net earn net cash provid
depreci amort net
pension settlement amort
divestitur gain royalti
loss/ gain equiti invest
chang oper asset liabil
net provid oper activ
sale matur market secur
purchas market secur
divestitur proce
acquisit payment
net use /provid invest activ
issuanc long-term debt
repay long-term debt
repurchas common stock
net use financ activ
effect exchang rate equival
increas equival
equival begin year
equival end year
earn cont op margin
annual report bristol myer squibb net profit
nyse report net profit year-end decemb
previou year earn per share ep
major chang compar previou year
total revenu
ebit margin
ebit total asset
good sold sale
profit tax sale
sale market expens sale
debt equiti
total liabil total asset
work capit total asset
retain earn total asset
total current asset total asset
net tangibl asset per share
total non-curr asset total asset
current debtor total asset
fix asset total asset
total revenu total asset steadi
tax expens sale
current ratio steadi
intang total asset
year-on-year comparison per share figur
year-on-year comparison perform ratio
total debt net tangibl asset
total liabil ebitda
total liabil oper
current ratio
common size ratio asset
total non-curr asset total asset
total current asset total asset
intang total asset
current debtor total asset
fix asset total asset
common size ratio sale
good sold sale
profit tax sale
sale market expens sale
tax expens sale
five-year record growth perform
last year total revenu averag ebitda averag net profit averag compound annual
growth rate compound-annual-growth-rate averag total revenu net profit ebitda
five-year record ebitda oper profit net profit roe roa roce
net profit margin average figur
return equiti
return asset
return capit employ
profit tax
oper cash flow
sale
past year incom tax profit tax increas
base issu equiti share market
capitalis billion nyse largest
compani total revenu
today announc quarterli dividend
per share ex dividend date thursday januari
record date friday januari
payabl monday februari
report buy sell trail month continu
share
share
report institut buy sell share
hold end quarter
report hold institut decemb
total report hold institut share
report hold institut
issu capit
net buying/ sell institut trail month ttm
america corp de
usd valu
new york mellon corp
state tennesse treasuri
treasur state north
teacher retir system texa
new patent issu us pto
view detail click patent link
triazolon tetrazolon inhibitor
antibodi use
prodrug imidazotriazin compound inhibitor
inhibitor indoleamin method use
heteroaryl substitut pyridyl compound use kinas modul
method treat cancer use immun checkpoint inhibitor
nucleic acid encod antibodi polypeptid antagon
macrocycl inhibitor protein/protein interact
antibodi use thereof
amide-substitut heterocycl compound use modul and/or ifn alpha
cyclic dinucleotid anti-cancer agent
composit compris combin nivolumab ipilimumab
apj agonist
toll-lik receptor agonist heteroatom-link aromat moieti conjug thereof
method use therefor
carbohydr content molecul
antibodi glucocorticoid-induc tumor necrosi factor receptor gitr use thereof
toll-lik receptor agonist pyridin pyrazin moieti conjug thereof
method use therefor
combin anti-kir antibodi treat multipl myeloma
anti-ico agonist antibodi use thereof
method treat patient risk costimul blockad resist reject belatacept
toll-lik receptor agonist heterobiaryl moieti conjug thereof method
macrocycl factor xia inhibitor
imidazopyridazin compound use modul and/or ifn alpha respons
antibodi enhanc agonist activ
toll-lik receptor agonist benzotriazol moieti conjug thereof method
use therefor
fibronectin bind domain reduc immunogen
antibodi glucocorticoid-induc tumor necrosi factor receptor gitr use thereof
toll-lik receptor agonist tricycl moieti conjug thereof method use
method use human fc-bear igg antibodi polyethylen glycol
tricycl sulfon ror gamma modul
substitut tetrahydrocarbazol carbazol carboxamid compound
method use antibodi polypeptid antagon treat ibd
treatment hematolog malign antibodi
imidazothiadiazol imidazopyrazin deriv proteas activ inhibitor
treat platelet aggreg
fibronectin base scaffold domain protein bind myostatin
bind polypeptid imag
triazolopyridin inhibitor myeloperoxidas
nucleic acid polypeptid use immunomodul
antiprolif compound conjug made therefrom
inhibitor treatment cancer
inhibitor treatment cancer
apj agonist
use antibodi combin antibodi cancer treatment
method treat diseas associ fibrosi use modifi polypeptid use
optim antibodi bind lymphocyt activ use thereof
aryl dihydropyridinon piperidinon inhibitor
method treatment use mutant molecul
method treat inflamm bispecif antibodi
cyclic compound use modul tnf alpha
pyrimidinon factor xia inhibitor
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
inhibitor indoleamin method use
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
tricycl heterocycl compound use inhibitor tnf
cancer immunotherapi disrupt signal
substitut inhibitor
phosphin oxid alkyl amid substitut heteroaryl compound modul and/or ifn
seco-cyclopropapyrroloindol compound antibody-drug conjug thereof method make
use
antibody-drug conjug tubulysin analog enhanc stabil
imidazopyridazin compound use modul and/or ifn- alpha respons
tricycl sulfon ror gamma modul
fibronectin base scaffold protein improv stabil
modifi relaxin polypeptid compris pharmacokinet enhanc use thereof
optim antibodi bind lymphocyt activ use thereof
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
stabl subcutan protein formul use thereof
devic method test inspect integr contain
anti-ico agonist antibodi use thereof
fibronectin base scaffold domain protein bind myostatin
treatment waldenstroom macroglobulinemia
thiazolyl- thiadiazolyl-substitut pyridyl compound use kinas inhibitor
method treat cancer administ igf-ir bind molecul
fc fusion protein compris novel linker arrang
quinazolin potassium ion channel inhibitor
triazolopyridin inhibitor myeloperoxidas
substitut aza benzofuran compound treatment hepat
substitut tetrahydroisoquinolin compound factor xia inhibitor
bristol-my squibb compani bm engag discoveri develop licens manufactur market
distribut sale pharmaceut nutrit product compani two segment pharmaceut
nutrit segment made global pharmaceut intern consum
medicin busi nutrit segment consist mead johnson nutrit mead johnson primarili
infant formula children nutrit busi januari compani complet divestitur bristol-
myer squibb medic imag medic imag avista capit partner june bm acquir kosan
bioscienc inc develop oncolog product august compani complet divestitur
convatec busi cidron healthcar limit affili nordic capit fund vii decemb
bm complet sale brand busi egypt glaxosmithklin
board manag creation sharehold valu
board director year sinc appoint
develop suppli
head strategi an
chief complianc
giovanni caforio chief execut offic bristol-
myer squibb sinc may serv
compani board director sinc june may
assum role chairman board
ceo giovanni led compani focu research
develop transform medicin includ
lead portfolio immunotherapi fundament
chang way cancer treat leadership bm
evolv oper model order increas speed
background physician giovanni help
strengthen compani patient-focus cultur -- one driven
innov speed account passion leader
focus busi valu compani cultur
promot reward divers inclus
prior becom ceo giovanni serv chief oper
offic respons lead fulli integr world-wide
commerci organ companywid function
enterpris servic global manufactur suppli
preced work compani chief commerci
giovanni join bristol-my squibb vice presid
gener manag itali world-wide medicin group
assum ad respons greec israel
south east europ appoint
senior vice presid european market brand
commerci reloc us assum
role senior vice presid oncolog
oncolog immunolog becom presid
compani organ prior join bristol-
myer squibb giovanni spent year
number leadership posit
born educ itali giovanni receiv
univers rome
charl bancroft respons compani world-wide
financ oper includ controllership area tax
treasuri audit servic procur strateg initi
global commerci manufactur financ
oper charli also respons busi
develop strategi allow integr approach
financi plan busi develop strategi
support compani effect meet long-term
goal charli join compani kpmg
sinc held posit increas respons within financ
organ includ intern assign
commerci oper respons latin american
east africa canada japan sever countri
pacif rim charli receiv bachelor scienc degre
account drexel univers master busi
administr templ univers
mr bonney age serv execut chair board
inc clinical-stag healthcar compani
chemistry-driven approach leverag microbiom
organ treat diseas improv human health
serv role sinc august serv chief
execut offic chairman june august
januari juli third
ventur llc previous mr bonney serv chief execut
offic member board director cubist
pharmaceut inc acquir merck co inc
januari june decemb prior
cubist vice presid sale market
inc prior join mr bonney spent eleven year
rang commerci oper
strateg role end career nation busi
mr bonney chair board director alnylam
pharmaceut inc also
current serv member board director
sarepta inc
previous serv member board director
inc inc
previous serv celgen board director
member execut nomin
govern complianc committe
mr bonney former board member tekla capit
manag llc pharmaceut
manufactur associ biotechnolog
industri organ
director life scienc care gulf main
research institut serv board non-profit
dr vousden age senior group leader
franci crick institut london sinc februari chief
scientist cancer research uk cruk sinc juli
serv director cruk beatson
institut glasgow prior held leadership role
nation cancer institut maryland
dr vousden bring board year
experi lead ground break cancer research
fellow royal societi serv member
scientif advisori board centro nacion de investigacion
oncologica grail inc ludwig institut cancer research
pmv pharma swiss institut
experiment cancer research dr vousden also council
member european molecular biolog organ
mr robert bertolini cpa independ director
compani mr bertolini serv presid chief
offic bausch lomb incorpor februari
august acquisit
previous serv execut vice presid chief
financi offic schering-plough corp novemb
novemb merger merck co
respons tax account financi asset
manag prior join schering-plough mr bertolini spent
year pricewaterhousecoop llp ultim lead
ms yale age serv advisori partner bain
compani work sinc ms yale
serv number leadership role bain
leader build bain healthcar practic last
year spent career advis health care provid
across full continuum care health insur privat
equiti investor invest health care servic bring
board deep knowledg us healthcar system
current chair board cross shield
massachusett serv board inc
previous ms yale serv board variou
healthcar provid payer kindr healthcar inc post-
servic america home care neighborcar inc
institut pharmaci also serv number advisori
board includ harvard busi school healthcar
initi health polici manag depart
harvard chan school public health
also serv non-profit board bridgespan
group truste reserv conserv
dr haller age serv sinc ophthalmologist-in-
chief will hospit philadelphia pa hold
william tasman endow chair professor
chair depart ophthalmolog sidney kimmel
medic colleg thoma jefferson univers thoma
magna cum laud graduat princeton dr haller receiv
degre harvard medic school train
wilmer institut john hopkin serv
first femal chief resid join john hopkin
faculti held katharin graham chair
ophthalmolog move lead will
one world renown retina surgeon dr haller
innov translat advanc blind mani
telemedicin combat health care dispar elect
nation academi medicin held mani leadership
role medicin past member board truste
princeton univers consult children hospit
philadelphia previous serv celgen board
director member audit committe
mr storch age serv chief execut offic
oper depart store includ sak fifth avenu
outfitt sak kaufhof inno e-commerc
busi gilt novemb januari serv
chairman chief execut offic storch advisor
also serv chairman toy us inc februari
novemb chief execut offic toy us
februari may prior join toy us mr
storch serv vice chairman target corpor join
senior vice presid strategi serv
role increas senior next year prior
join mr storch partner mckinsey compani
director fanat inc
skill experi retail veteran
year experi mr storch provid board valuabl
busi leadership manag insight includ
expertis lead organ global oper give
keen understand issu face multi-national
busi qualiti make valu member
audit committe addit prior servic
compens committe anoth public compani posit
well serv member compens
mr grobstein age retir vice chairman ernst
young llp independ regist public account firm mr
grobstein work ernst young
admit partner
serv vice chairman intern oper
vice chairman plan market
industri servic vice chairman
account audit servic
serv board truste execut committe
treasur central park conserv
also serv board director peer health
mr paliw age serv chairman presid
chief execut offic harman intern industri inc
connect technolog compani automot consum
enterpris market sinc juli mr paliw serv
presid chief execut offic harman sinc juli
prior join harman mr paliw serv member
group execut committe abb ltd provid industri
autom power transmiss system servic
januari june
mr paliw also serv presid global market
technolog abb ltd januari june
chairman chief execut offic abb north america
januari june presid chief
execut offic abb autom technolog divis
octob decemb
mr paliw serv board busi advisori council
farmer school busi miami univers
india busi council usibc board director also
member ceo busi roundtabl washington
 india ceo forum
mr arduini age presid chief execut
offic integra lifesci hold corpor global
medic technolog compani sinc januari current
serv member integra board director serv
presid chief oper offic integra novemb
januari join integra mr arduini
corpor vice presid presid medic deliveri
baxter healthcar prior join baxter mr
arduini work gener electr healthcar spent
much year varieti manag role
domest global busi culmin lead global
function imag busi mr arduini also serv board
director advam advanc medic technolog
associ board director mdic medic devic
innov consortium board director
skill experi year healthcar
industri mr arduini bring board extens leadership
busi oper experi particularli respect
manufactur sale medic technolog devic
addit mr arduini experi serv public compani
chief execut offic former chief oper offic
posit well serv member audit committe
serv chief execut offic shire plc
chairman board also
serv director incorpor
chairman presid chief execut offic
director mr
emmen serv presid world-wide pharmaceut
merck kgaa chief execut offic
commerci oper astra merck inc
sale market administr posit merck
co inc
skill experi year
biopharmaceut industri mr emmen bring board
signific expertis manag busi develop
busi oper particularli respect strategi
team effect mr emmen strong leadership qualiti
industri knowledg posit well provid valuabl insight
manag fellow board member issu
face compani serv member
compens manag develop committe
member scienc technolog committe
mr laci age former non-execut chairman dave
buster entertain inc previous serv
chairman chief execut offic sear roebuck co
vice chairman chief execut offic
successor sear hold corpor
mr laci also serv vice chairman sear hold
corpor recent mr laci serv
senior advisor oak hill capit partner privat
equiti invest firm
truste fidel fund california chapter
mr laci director center advanc studi
behavior scienc stanford univers
year financi industri theodor ted
samuel age bring board extens busi
oper experi particularli respect econom
capit market invest decis make mr samuel
former presid capit guardian trust compani
former global equiti portfolio manag
capit group one promin invest
manag organ world
capit group serv numer manag
invest committe eye toward long-term
sharehold valu creation also serv co-chair tuft
presid council harvard west coast council
sandi leung serv legal advisor board director
compani execut respons shape
compani legal strategi sandi also respons
secur philanthropi
acceler pace scienc government polici
regul overal global complex across industri
requir us even agil ever say sandi
legal team bring strateg valu across aspect
busi practic sound counsel guid
compani mission help patient
sandi join bristol-my squibb staff attorney
litig depart becam assist counsel
one year later name associ counsel
sandi appoint posit counsel corpor
secretari appoint act gener counsel
name gener counsel sandi
name execut vice presid
prior join compani sandi prosecutor
advic aspir manag posit
good will hard work
bring good excel judgment expertis tabl
import must great person integr
someon peopl trust peopl trust feel
comfort seek advic also respect peopl
superior everyon
sandi earn law degre boston colleg law
bachelor degre tuft univers
dr christoph boerner ph execut vice presid
chief commerci offic compani recent
serv compani head intern market
octob august join compani
februari head commerci organ
serv role octob prior join
compani inc serv
execut vice presid commerci
senior vice presid commerci
join mr boerner dendreon
corpor led market team
work genentech member roch group
serv varieti commerci role includ
director market avastin director avastin franchis
strategi associ director oncolog market develop
chief complianc ethic offic adam lead
compani effort ensur oper conduct
complianc ethic busi practic principl
integr well law regul market
oper addit report gener counsel
ceo adam also report chair audit committe
board director
focu ethic integr critic success
compani say adam ensur maintain unwav
focu highest standard help ensur meet
commit made patient employe
commun work sharehold
adam recent serv vice presid associ
gener counsel support organ prior
adam provid strateg counsel compani leadership
polici issu repres compani extern
lead global corpor polici
adam join bristol-my squibb held divers
set role progress increas respons within
law depart counsel pharmaceut
busi adam advis oncolog virolog
immunosci busi unit regulatori complianc
contractu commerci matter also intern
role singapor pari franc led law
depart compani asia pacif japan
europ middl east africa region prior join bristol-
myer squibb adam law firm sedgwick
detert moran arnold new york
adam hold psycholog brandei univers
 fordham univers
ann powel judg global head human resourc
bristol-my squibb whose mission discov develop
deliv innov medicin help patient prevail
seriou diseas ann direct respons drive
corpor global capabl talent manag cultur
organiz effect tie directli busi
perform ann work across enterpris support bristol-
myer squibb commit creat energ work
experi cultur power divers broadli
inclus individu encourag exceed
potenti inspir make innov contribut
patient global commun live work
courag passion workforc truli inspir
drive even higher level engag make differ
live patient say ann ann industri experi
expertis lie execut compens leadership develop
chang manag diversity/inclus train design
deliveri talent acquisit labor relat merger
acquisit divestitur start-up
karen santiago appoint senior vice presid control
compani effect februari join bristol-
myer squibb compani serv multipl role
increas respons recent
serv vice presid financ global manufactur
suppli vice presid financ us
puerto rico commerci sinc vice
presid lead enabl function financ
transform ms santiago financ
 account certifi public account
technolog organ posit compani success
rapidli evolv digit age focus ensur
compani inform asset oper reliabl
access secur drive digit compani
adopt new approach digit health continu
innov approach long-term partnership key servic
excit time lead team advanc
technolog provid new opportun streamlin live
unpreced way includ manag health paul
said deliv digit capabl acceler compani
work bring innov medicin patient
challeng honor
throughout experi domest intern high-
tech consum packag good biopharmaceut
compani paul career focus strateg
leverag inform technolog drive superior perform
join bristol-my squibb paul held posit kraft
gener food hewlett-packard member
research board serv board truste
paul bachelor degre electr engin
master degre comput scienc steven institut
technolog complet program manag
develop harvard busi school program
leadership develop imd switzerland
price period/numb period
return asset
volum weight averag price vwap summat
turnov divid total volum period
present valu invest year/ year ago
price close today/pric close period ago rank
percentil within entir market
number share trade period/averag number share
trade period
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
nasdaq stock market hong kong exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
